Carrier‐Free Nanoassembly of Curcumin–Erlotinib Conjugate for Cancer Targeted Therapy

Anticancer drug‐loaded nanoparticles have been explored extensively to decrease side effects while improving their therapeutic efficacy. However, due to the low drug loading content, premature drug release, nonstandardized carrier structure, and difficulty in predicting the fate of the carrier, only a few nanomedicines have been approved for clincial use. Herein, a carrier‐free nanoparticle based on the self‐assembly of the curcumin–erlotinib conjugate (EPC) is developed. The EPC nanoassembly exhibits more potent cell killing, better antimigration, and anti‐invasion effects for BxPC‐3 pancreatic cancer cells than the combination of free curcumin and erlotinib. Furthermore, benefiting from both passive and active tumor targeting effect, EPC nanoassembly can effectively accumulate in the tumor tissue in a xenograft pancreatic tumor mouse model. Consequently, EPC effectively reduces the growth of pancreatic tumors and extends the median survival time of the tumor‐bearing mice from 22 to 68 days. In addition, no systemic toxicity is detected in the mice receiving EPC treatment. Attributed to the uniformity of the curcumin–erlotinib conjugate and easiness of scaling up, it is expected that the EPC can be translated into a powerful tool in fighting against pancreatic cancer and other epidermal growth factor receptor positive cancers. A carrier‐free nanoassembly is fabricated from a curcumin–erlotinib conjugate (EPC), which has a uniform structure. Due to the existence of erlotinib outlayer, EPC effectively accumulates in the tumor and enters EGFR positive cancer cells. Benefiting from the synergetic effect of curcumin and erlotinib, EPC reduces tumor burden and extends the survival time of the animal with pancreatic cancer.